109 related articles for article (PubMed ID: 15950748)
1. Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases.
Murakami E; Basavapathruni A; Bradley WD; Anderson KS
Antiviral Res; 2005 Jul; 67(1):10-7. PubMed ID: 15950748
[TBL] [Abstract][Full Text] [Related]
2. Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3'-fluorothymidine analogue 5'-triphosphates.
Wińska P; Miazga A; Poznański J; Kulikowski T
Antiviral Res; 2010 Nov; 88(2):176-81. PubMed ID: 20739003
[TBL] [Abstract][Full Text] [Related]
3. Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design.
Kukhanova M; Li X; Chen SH; King I; Doyle T; Prusoff W; Cheng YC
Mol Pharmacol; 1998 May; 53(5):801-7. PubMed ID: 9584205
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
[TBL] [Abstract][Full Text] [Related]
5. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP.
Murakami E; Ray AS; Schinazi RF; Anderson KS
Antiviral Res; 2004 Apr; 62(1):57-64. PubMed ID: 15026203
[TBL] [Abstract][Full Text] [Related]
6. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
Harris KS; Brabant W; Styrchak S; Gall A; Daifuku R
Antiviral Res; 2005 Jul; 67(1):1-9. PubMed ID: 15890415
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase.
Feng JY; Anderson KS
Biochemistry; 1999 Jan; 38(1):55-63. PubMed ID: 9890882
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
9. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
10. Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
Sohl CD; Kasiviswanathan R; Kim J; Pradere U; Schinazi RF; Copeland WC; Mitsuya H; Baba M; Anderson KS
Mol Pharmacol; 2012 Jul; 82(1):125-33. PubMed ID: 22513406
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamide.
Herschhorn A; Oz-Gleenberg I; Hizi A
Biochemistry; 2008 Jan; 47(1):490-502. PubMed ID: 18052256
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis.
Matamoros T; Kim B; Menéndez-Arias L
J Mol Biol; 2008 Feb; 375(5):1234-48. PubMed ID: 18155043
[TBL] [Abstract][Full Text] [Related]
13. Probing interactions between HIV-1 reverse transcriptase and its DNA substrate with backbone-modified nucleotides.
Marx A; Spichty M; Amacker M; Schwitter U; Hübscher U; Bickle TA; Maga G; Giese B
Chem Biol; 1999 Feb; 6(2):111-6. PubMed ID: 10021419
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
15. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
16. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.
Feng JY; Murakami E; Zorca SM; Johnson AA; Johnson KA; Schinazi RF; Furman PA; Anderson KS
Antimicrob Agents Chemother; 2004 Apr; 48(4):1300-6. PubMed ID: 15047533
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
[TBL] [Abstract][Full Text] [Related]
18. Introduction of the alpha-P-borano-group into deoxynucleoside triphosphates increases their selectivity to HIV-1 reverse transcriptase relative to DNA polymerases.
Dobrikov MI; Grady KM; Shaw BR
Nucleosides Nucleotides Nucleic Acids; 2003 Mar; 22(3):275-82. PubMed ID: 12816386
[TBL] [Abstract][Full Text] [Related]
19. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment.
Yamanaka H; Gatanaga H; Kosalaraksa P; Matsuoka-Aizawa S; Takahashi T; Kimura S; Oka S
J Infect Dis; 2007 May; 195(10):1419-25. PubMed ID: 17436221
[TBL] [Abstract][Full Text] [Related]
20. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs.
Feng JY; Johnson AA; Johnson KA; Anderson KS
J Biol Chem; 2001 Jun; 276(26):23832-7. PubMed ID: 11328813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
